We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Market Opportunities Appear for Improved Swine Flu Diagnostic Tests

By LabMedica International staff writers
Posted on 07 May 2009
The outbreak of swine flu is highlighting the public health importance of improved testing techniques and providing market opportunities related to the disease.

There will be a distinct market impact on both immunoassay and molecular test makers, according to a new report released by Kalorama Information (Rockville, MD, USA). The makers of certain tests will benefit both in terms of sales and more broadly in the recognition that their products play a vital role in making the public health community significantly better prepared for this possible pandemic than in 1968 or before.

Rapid immunoassays, the clinical usefulness of which is limited under normal conditions, will see an increased profile. For the most part, sales of these products depend on the severity of the influenza season, which has been mild (with subsequent disappointing sales) in recent years. The advent of the swine flu will have a positive, albeit short-term, impact on revenues.

"Under normal circumstances, most patients do not visit a doctor or hospital to be tested for the flu until after the period when the detectable virus is being shed, in which case rapid testing is unhelpful," notes Shara Rosen, the author of the report. "However, this scenario changes in the setting of an epidemic or pandemic alert when people are more sensitized to the danger of the illness. And in a pandemic situation with limited therapeutic supply, rapid immunoassays provide important clinical decision-making information."

Molecular tests will also feel the impact, according to the report. Already replacing culture as the dominant technique for strain determination, molecular testing development and investment will be further driven by the importance of sufficient capacity and speed that a potential pandemic highlights.

Kalorama Information conducts independent market research in the life sciences, as well as supplying a full range of custom research services.

Related Links:
Kalorama Information


New
Gold Member
ANCA IFA
Kallestad Autoimmune ANCA IFA Complete Kit
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
New
Anti-Rubella IgG (Rubella IgG) Test
Rubella IgG AccuBind ELISA
New
Control Material
Blood Culture Identification Control Panel

Latest Molecular Diagnostics News

Early Blood Test Predicts Survival in Patients with Metastatic Prostate Cancer

POC Sepsis Test Delivers Fast, Accurate and User-Friendly Results in Critical Care Settings

Experimental Blood Test Improves Detection of Early-Stage Pancreatic Cancer